fda sued over tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA says shortage of GLP-1

Landmark trials including STEP 1 and STEP 2 (published in *New England Journal of Medicine*) demonstrated superior weight loss and lower dropout rates with stepwise escalation versus fixed-dose approaches

Medical literature does not report safety or efficacy data for this combination, leaving prescribing decisions in the absence of evidence

This increased liver echogenicity correlated with lipid accumulation, indicating the development of fatty liver

A number of GLP-1RAs are available for subcutaneous injection which differ in their molecular structure, size, half-life, and dosing interval (Fig

Notably, despite the presence of severe obesity, large-scale population cohort studies have revealed that individuals with MC4R -deficient obesity exhibit a unique metabolically protective phenotype

Joe's impossible biceps to today's Ginfluencer explosion